Tags

Type your tag names separated by a space and hit enter

The Combined therapy myo-inositol plus D-Chiro-inositol, in a physiological ratio, reduces the cardiovascular risk by improving the lipid profile in PCOS patients.
Eur Rev Med Pharmacol Sci 2013; 17(4):537-40ER

Abstract

BACKGROUND

Women with Polycystic Ovarian Syndrome (PCOS) present several factors that increase the cardiovascular risk, such as insulin resistance and dyslipidemia. Myo-inositol and D-chiro-inositol have been shown to improve insulin resistance, hyperandrogenism and to induce ovulation in PCOS women. However, their effects on dyslipidemia are less clear. The aim of the present study was to evaluate whether the combined therapy myo-inositol plus D-chiro-inositol (in a in a physiological ratio of 40:1) improve the metabolic profile, therefore, reducing cardiovascular risk in PCOS patients.

PATIENTS AND METHODS

Twenty obese PCOS patients [BMI 33.7 ± 6 kg/m2 (mean ± SD)] were recruited. The lipid profile was assessed by measuring total cholesterol, LDL, HDL and triglycerides before and after 6 months treatment with the combined therapy. Secondary end points included changes in BMI, waist-hip ratio, percentage of body fat, HOMA-IR and blood pressure.

RESULTS

The combined therapy myo-inositol and D-chiro-inositol improved LDL levels (3.50 ± 0.8 mmol/L versus, 3 ± 1.2 mmol/L p < 0.05), HDL (1.1 mmol/L ± 0.3 versus 1.6 mmol/L ± 0.4 p < 0.05) and triglycerides (2.3 ± 1.5 mmol/L versus 1.75 ± 1.9 mmol/L p < 0.05). Furthermore, significant improvements in HOMA-IR were also observed.

CONCLUSIONS

The combined therapy myo-inositol plus D-chiro-inositol is able to improve the metabolic profile of PCOS women, therefore, reducing the cardiovascular risk.

Authors+Show Affiliations

Institute of Obstetrics and Gynecology, ''Sapienza'' University of Rome, Italy.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

23467955

Citation

Minozzi, M, et al. "The Combined Therapy Myo-inositol Plus D-Chiro-inositol, in a Physiological Ratio, Reduces the Cardiovascular Risk By Improving the Lipid Profile in PCOS Patients." European Review for Medical and Pharmacological Sciences, vol. 17, no. 4, 2013, pp. 537-40.
Minozzi M, Nordio M, Pajalich R. The Combined therapy myo-inositol plus D-Chiro-inositol, in a physiological ratio, reduces the cardiovascular risk by improving the lipid profile in PCOS patients. Eur Rev Med Pharmacol Sci. 2013;17(4):537-40.
Minozzi, M., Nordio, M., & Pajalich, R. (2013). The Combined therapy myo-inositol plus D-Chiro-inositol, in a physiological ratio, reduces the cardiovascular risk by improving the lipid profile in PCOS patients. European Review for Medical and Pharmacological Sciences, 17(4), pp. 537-40.
Minozzi M, Nordio M, Pajalich R. The Combined Therapy Myo-inositol Plus D-Chiro-inositol, in a Physiological Ratio, Reduces the Cardiovascular Risk By Improving the Lipid Profile in PCOS Patients. Eur Rev Med Pharmacol Sci. 2013;17(4):537-40. PubMed PMID: 23467955.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The Combined therapy myo-inositol plus D-Chiro-inositol, in a physiological ratio, reduces the cardiovascular risk by improving the lipid profile in PCOS patients. AU - Minozzi,M, AU - Nordio,M, AU - Pajalich,R, PY - 2013/3/8/entrez PY - 2013/3/8/pubmed PY - 2013/6/19/medline SP - 537 EP - 40 JF - European review for medical and pharmacological sciences JO - Eur Rev Med Pharmacol Sci VL - 17 IS - 4 N2 - BACKGROUND: Women with Polycystic Ovarian Syndrome (PCOS) present several factors that increase the cardiovascular risk, such as insulin resistance and dyslipidemia. Myo-inositol and D-chiro-inositol have been shown to improve insulin resistance, hyperandrogenism and to induce ovulation in PCOS women. However, their effects on dyslipidemia are less clear. The aim of the present study was to evaluate whether the combined therapy myo-inositol plus D-chiro-inositol (in a in a physiological ratio of 40:1) improve the metabolic profile, therefore, reducing cardiovascular risk in PCOS patients. PATIENTS AND METHODS: Twenty obese PCOS patients [BMI 33.7 ± 6 kg/m2 (mean ± SD)] were recruited. The lipid profile was assessed by measuring total cholesterol, LDL, HDL and triglycerides before and after 6 months treatment with the combined therapy. Secondary end points included changes in BMI, waist-hip ratio, percentage of body fat, HOMA-IR and blood pressure. RESULTS: The combined therapy myo-inositol and D-chiro-inositol improved LDL levels (3.50 ± 0.8 mmol/L versus, 3 ± 1.2 mmol/L p < 0.05), HDL (1.1 mmol/L ± 0.3 versus 1.6 mmol/L ± 0.4 p < 0.05) and triglycerides (2.3 ± 1.5 mmol/L versus 1.75 ± 1.9 mmol/L p < 0.05). Furthermore, significant improvements in HOMA-IR were also observed. CONCLUSIONS: The combined therapy myo-inositol plus D-chiro-inositol is able to improve the metabolic profile of PCOS women, therefore, reducing the cardiovascular risk. SN - 1128-3602 UR - https://www.unboundmedicine.com/medline/citation/23467955/The_Combined_therapy_myo_inositol_plus_D_Chiro_inositol_in_a_physiological_ratio_reduces_the_cardiovascular_risk_by_improving_the_lipid_profile_in_PCOS_patients_ L2 - http://www.europeanreview.org/article/3314 DB - PRIME DP - Unbound Medicine ER -